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ABSTRACT:
Medial collateral ligament tears are the most common knee ligament injury.
Extent of injury is graded on a three-point scale. The mainstay of treatment for isolated
tears is physical therapy; however, grade II and III tears require more intensive therapy.
Platelet-rich plasma therapy is an autologous concentration of platelets prepared as an
injection to augment the healing process. We propose a randomized controlled trial
investigating the efficacy of platelet-rich plasma injection for patients with acute
grade II or III medial collateral ligament tears. Results will be quantified by mean
decrease in Visual Analog Scale scores at two, four, and six weeks. We hypothesize that
injection of platelet-rich plasma combined with physical therapy will significantly
decrease pain scores when compared to standard physical therapy. This study will
evaluate a new treatment for acute isolated grade II and III medial collateral ligament
tears in decreasing pain and expediting return to activity.

v

CHAPTER 1: INTRODUCTION
1.1 BACKGROUND
1.1.1 Brief History of the Problem
The medial collateral ligament (MCL) of the knee is the most commonly injured
ligament at various athletic levels and ages1-6. The MCL is the primary resistor to valgus
stress and therefore the mechanism of injury is typically due to contact to the lateral
aspect of the knee causing excessive valgus stress4,7-10. The resulting injury can be
stratified by clinical grades, I, II, and III4,6. The treatment of MCL sprains, especially less
severe grade of injury, grades I and II, is mainly conservative with emphasis on
functional rehabilitation2,3,7,11,12. The rationale is that compared with the other knee
ligaments, the MCL has the most potential to heal after acute injury5,13. The definition of
an acute MCL injury is a date of injury less than three weeks before starting treatment14.
As the severity of the MCL injury increases, there is no consensus on optimal treatment.
With more severe grade II and isolated grade III injuries, conservative versus surgical
treatment is considered. However, studies have shown that surgical intervention has not
yielded a significant clinical benefit after two years, and has even been implicated in
poorer outcomes in some studies15,16. Therefore, conservative treatment is often chosen
for isolated grade II and III tears with the resulting time lost due to injury ranging from
three to eight weeks7,9,17,18. This loss of time due to injury indicates the need for
augmentation of current functional rehabilitation for isolated grade II and III MCL tears.
1.1.2 Epidemiology and Etiology of Medial Collateral Ligament (MCL) Tears
MCL injury is a particularly common injury in athletes and accounts for up to
7.9% of all knee injuries8,19. MCL injury is the most common knee injury in high school,

1

collegiate, and professional football7,17. Annually, 24.2 per 100,000 high school football
players tear their MCL3,7,17,18. A study examining the distribution of MCL injuries among
the United States Military Academy and found an overall incidence rate of 7.27 per 1000
person-years1. Men were 2.6 times more likely to sustain an MCL tear than women1-3.
Other studies report that injury to the MCL accounted for 29% of all knee injuries in
Division I Football in the United States9. Similarly, MCL injury is the most common
knee ligament injury in professional soccer20. Players were 9 times more likely to be
injured in a game setting versus during practice and injury was often due to contact with
another player or object20. This differs from another common injury, the anterior cruciate
ligament (ACL) in which injury due to contact was only the case for 37% of patients21.
1.1.3 Medial Collateral Ligament Pathophysiology
The medial collateral ligament consists of a superficial and a deep layer2,7.The
superficial MCL is the main constraint to valgus stress and is the largest structure of the
medial knee3,6,7,10,22. The classic model of healing involving hemorrhage, inflammation,
cellular proliferation, and tissue remodeling, and the abundant vascular supply of the
superficial MCL allows this process to occur3,23,24. The deep MCL is thicker than the
superficial MCL and runs parallel to it until it meets the joint capsule of the knee7,21. The
superficial MCL is more commonly injured than the deep MCL, and MRI imaging is a
common way to confirm the grade of the sprain21. Grade III tears are commonly
associated with injury to the deep MCL but initially might not be clinically appreciated
which can later cause residual pain or failure of conservative treatment5,21.
1.1.4 Diagnosis of Medial Collateral Ligament Tears

2

Diagnosis of MCL injury begins with physical exam with the most common
findings being ecchymosis and painful swelling over the medial joint line6,14,17
accompanied by tenderness over the medial epicondyle, joint line, or the proximal tibia10.
The American Medical Association classifies MCL tears into grades I, II, III3. Grade I
includes localized tenderness without evidence of instability, grade II includes localized
tenderness and partially torn MCL and posterior oblique fibers, and grade III is defined as
complete disruption and instability with applied valgus stress3. Tears are further graded
by valgus laxity with 1+ encompassing tears that reveal 0-5 mm laxity with a firm
endpoint25 on physical exam, 2+ with 6-10 mm laxity with a firm endpoint25, and 3+ > 10
mm laxity with a soft endpoint (see Table 1)3,6,14,18,25,26. In practice, a functional grading
system is often implemented which requires valgus stress testing at 0 and 30 degrees. If
minimal laxity and pain are present with valgus stress at 0 and 30 degrees, a grade I tear
is indicated25. Findings consistent with a grade II injury are laxity at 30 degrees but
stability at 0 degrees; grade III findings include laxity at both degrees25. This pattern of
laxity is often indicative of a concomitant cruciate ligament injury. In the setting of
ligamentous laxity, it is important to confirm intact neurovascular status with pedal
pulses or ankle-brachial index25.
After physical examination indicates a MCL tear, imaging follow-up is
recommended especially in the acute setting25. Studies indicate that the acute phase of
injury can limit detection of the classic findings for MCL tear during physical
examination25, and imaging can then confirm grade of tear, combined ligament injuries,
avulsions or fractures, and other meniscal or chondral damage25. Imaging modalities may
include radiographs and MRI. The recommended radiograph is a weight-bearing standard
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four view knee series with anteroposterior and lateral being the minimum views
requried14,17,18,25. Isolated MCL tears often result in normal knee radiographs, but joint
widening findings or asymmetry sometimes indicate multiligamentous involvement25.
Additionally, radiographs can detect avulsion fracture or other acute bony injury.
MRI diagnosis of MCL injury is reported to be 87% accurate which challenges
the current clinical gold standard of diagnosis9,21. Grade I injury on MRI is typically
defined as an intact MCL with microscopic tears of surrounding individual fibers, grade
II involves visible changes or high intrasubstance signal to the MCL, and grade III
represents complete ligamentous discontinuity with laxity or waviness21. Visualization of
both the superficial and deep MCL are best seen on T1 and T2 weighted images on the
coronal series10.
Table 1: Classification of MCL Tears by Grade
Classification

Definition
Localized tenderness without instability
Firm endpoint
Localized tenderness and partially torn medial
collateral and posterior oblique fibers
Firm endpoint
Complete disruption; instability with valgus
stress
Soft or no endpoint

Grade I
Grade II

Grade III

Clinical Subjective
1+
2+
3+

3-5 mm laxity
6-10 mm laxity
>10 mm laxity

1.1.5 Medial Collateral Ligament Treatment
The treatment of MCL sprains, especially for grade I and II tears, is mainly
conservative2,3,7,11,12,17. Isolated grade I tears can be treated effectively with rest, ice,
compression, and elevation especially during the first 72 hours6. Non-steroidal antiinflammatory drugs can be used to alleviate symptoms6. An example rehabilitation
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protocol includes use of a hinged knee brace to protect against valgus stress and early
emphasis on range of motion6. The goal range of motion before progression to walking
outdoors or on a treadmill is 90 degrees with progression to running at 75% of maximum
speed6. Full resolution of pain is a common marker of recovery. Treatment of grade II
injuries can be similar to that of grade I with return to activity being allowed once
quadricep strength is 90% or greater than the contralateral quadricep and regular activity
or agility testing does not cause pain6.
Treatment of grade III MCL tears becomes more complicated as there is the
potential for more severe instability, entrapment, or avulsion, all of which have been
proposed as criteria for surgical intervention14. Some guidelines suggest that the stability
of the sprain is a key factor in the decision between surgical and conservative
treatment14,17,18. Studies have also shown that in grade III MCL sprain, the risk of
additional ligament injury is up to 78% and commonly involves the ACL11,15,17,27. Of this
group of patients, a combined MCL-ACL injury accounts for over 90% of medial
ligament injuries11. In this case, usual practice is to delay surgery for five to eight weeks
to allow the MCL an opportunity to heal before ACL reconstruction14,18. The decision
becomes whether to simultaneously repair the MCL during ACL reconstruction surgery.
One recent study found no significant pain difference in patients who underwent
simultaneous MCL repair and ACL reconstruction versus patients who only underwent
ACL reconstruction while another study found a worse outcome with concomitant repair
of both ligaments16,28. The importance of these studies is that they support conservative
treatment for isolated grade III MCL tears.
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Some studies argue that grade III isolated tears without evidence of significant
valgus instability are candidates for conservative treatment and have even shown
superiority to operative treatment9,18,28,29. This includes functional rehabilitation, physical
therapy, and use of a hinged brace14,17. There has also been a transition away from
prolonged immobilization towards crutches and early mobilization18,22,28-31. The rationale
is that this approach improves longitudinal alignment and concentration of cells and
collagen4,10,18. The goal of physical therapy is to restore quadriceps function, improve
knee range of motion, and resolve knee edema18. For the first three to four weeks,
exercises include the use of a stationary bike and exercises that do not require lateral
movements to protect the knee from valgus stress18. When the clinical exam indicates
healing by decreased pain and laxity with valgus stress testing, return to full activity or
sport becomes the goal18. Even with physical therapy efforts, grade III injury recovery
averages five to eight weeks7,18,29. Additionally, clinicians worry about failed
conservative treatment of grade II and III MCL tears in some cases can leading to
persistent medial instability, weakness, and osteoarthritis17.
1.1.6 Benefits of Platelet-Rich Plasma
The basis for the benefit of platelet-rich plasma (PRP) is that it is an autologous
concentration of platelets above that which is normally in whole blood24,32-34. This is
achieved by centrifuging whole blood to separate it into components based on
density33,34. The resulting platelet layer is located in highest concentration in the plasma
and includes an increased concentration in of various growth factors, all of which
enhance the body’s natural healing process33-36. PRP has multiple components including
platelets, leukocytes, and red blood cells33. When platelets come into contact with an
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injured area during normal tissue healing, they degranulate and release growth factors37.
These numerous growth factors upregulate protein metabolism, stimulate
neovascularization, and are proposed to accelerate healing24,34,37. Additionally, growth
factors synthesize collagens and over 300 extracellular matrix anabolic proteins38. The
process of preparing a PRP injection results in a three to fivefold increase in the
concentration of platelets and therefore growth and differentiation factors in comparison
to the body’s natural environment.24,34. This heightened concentration theoretically could
be the difference in complete versus incomplete recovery from an acute injury.
The majority of PRP applications in orthopaedic injuries has focused on tendon
injuries and tendinopathies and have shown evidence that PRP is effective in the
treatment of tendinopathy37,39,40. To date, randomized controlled trials investigating the
effect of PRP on MCL pathology has not been conducted. However, several case studies
have reported positive results in terms of decreased time lost to injury and return to
play41-43. Augmentation with PRP has seen success in other populations, and although it
has been applied for MCL tears in practice, a confirmatory trial has not been conducted.
1.2 STATEMENT OF THE PROBLEM
The standard of care for isolated medial collateral ligament tears is a physical
therapy regimen emphasizing early range of motion and progression to weight bearing
exercises12. This type of functional rehabilitation is generally effective for grade I and II
tears as evidenced by patient outcomes and return to activity at an average of two to three
weeks6,12. Still, more severe grades of MCL tears have a longer recovery and carry the
risk of residual medial instability with failed physical therapy. The treatment of grade III
injuries is also a discussion of non-operative versus operative treatment6. Non-operative
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treatment of grade III tears has been successful but results in a longer loss of time due to
injury than grades I or II tears15,28,29. Additionally, grade III MCL injuries have a high
incidence of concomitant ligament damage, with ACL rupture being the most common15.
Surgical reconstruction of the ACL is the standard of care in high-demand athletes, but
management of combined MCL-ACL injuries remains controversial15,44. A recent study
showed no significant difference in outcomes between conservative versus operative
management of the MCL in the setting of ACL reconstruction which, in turn, supports
non-operative treatment of isolated MCL tears15.
Platelet-rich plasma injections have been proposed to augment the body’s natural
healing process24. Application of PRP injections in the MCL injured population has three
potential benefits. The first is that superficial MCL is abundantly vascularized, follows
the classic model of healing, and would therefore potentially benefit from platelet-rich
plasma by the addition of a high concentration of the biological components needed for
tissue healing3. Secondly, MCL tears that involve the deep MCL, especially those that are
not clinically discovered, can cause lingering pain. A PRP injection would flood the
MCL area and possibly allow for more tissue healing of the deep MCL. Finally, although
our study will include a broader population of patients with MCL injuries, athletes at
various levels who are focused on returning to play as soon as possible would particularly
benefit from a conservative treatment that decreases pain and promotes faster healing.
To date, two case reports of elite athletes with acute MCL sprain have described
favorable results with PRP injection quantified by time to return to play41,43. However,
there have been no randomized studies investigating the benefit of platelet-rich plasma on
recovery from MCL injury. There is a need for a blinded randomized controlled trial
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investigating PRP in the setting of MCL tears. Our study will examine platelet-rich
plasma as an adjuvant to physical therapy in comparison to a control group receiving a
placebo injection for isolated grade II and grade III MCL injuries, given the longer
recovery time associated with a more severe tear. Successful conservative therapy of
MCL injury avoids necessity for a surgical intervention and decreases time lost to injury.
The potential for platelet-rich plasma to contribute to the success of conservative therapy
will potentially provide a great benefit to our study population.
1.3 GOALS AND OBJECTIVES
The proposed study is a randomized, double blind, controlled trial examining the
efficacy of a platelet-rich plasma injection for patients with isolated grade II and grade III
medial collateral ligament tears. Both groups will undergo standard physical therapy for
MCL tears with emphasis on range of motion and early weight bearing12. The goal of this
study is to determine whether platelet-rich plasma is an effective adjuvant to conservative
treatment for acute isolated grade II and grade III MCL tears. The main objective of this
study is to determine the mean difference for a group of patients treated with PRP
between baseline Visual Analog Scale (VAS) scores and scores at two, four, and six
weeks compared with pain scores for a placebo injection group. Our study will evaluate
the efficacy of conservative treatment for more severe grades of MCL tears (II and III)
and investigate platelet-rich plasma as an adjunct to non-operative treatment.
1.4 HYPOTHESIS
Patients with isolated grade II or III medial collateral ligament tears aged 18-45
who are treated with platelet-rich plasmaa as an adjuvant to standard physical therapy will
have a statistically significant mean difference in Visual Analog Scaleb scores from
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baseline to two-, four-, and six-week follow-up in comparison to patients treated with a
placebo injectionc and standard physical therapyd. The expected clinically significant
effect size expected to be -3.6 +/- 2.3 at six-week follow-up.
1.5 DEFINITIONS
a. Platelet-Rich Plasma: Platelet-rich plasma (PRP) is an autologous concentration of
human platelets obtained by a venous blood draw, a centrifugation process to separate
out the plasma, and preparation as in injection with a three to fivefold increase in
growth factors to augment the body’s classic model of healing24. PRP injections are
also categorized by the abundance of neutrophils; denoted leukocyte-rich (LR-PRP)
for PRP preparations with an above average number of leukocytes, or leukocyte-poor
(LP-PRP) if below the average number of leukocytes24.
b. Visual Analog Scale (VAS): The Visual Analog Scale (VAS) is a 10 cm number line
beginning at 0 where the left endpoint is designated “no pain” and the right endpoint
is “worst pain imaginable”. The patient selects a point along the line that corresponds
to the pain he or she is feeling at the time of completion.
Figure 1: Visual Analog Scale (VAS)

c. Placebo injection: A standard placebo injection is 0.9% normal saline prepared in
with the same protocol as the intervention injection.
d. Standard physical therapy: Standard physical therapy for medial collateral ligament
tears include quadriceps and leg muscle strengthening and early range of motion
protocols followed by a progressive return to functional and sport-specific
movements in four to six weeks.
10
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CHAPTER 2: REVIEW OF THE LITERATURE
2.1 INTRODUCTION
A review of the literature was conducted between December 2019 and May 2020
using Pubmed, Scopus, Ovid, ScienceDirect, and Cochrane Medical Library. The MeSH
terms used to search these databases included “collateral ligaments/injuries”, “ligaments,
articular/injuries”, “ligaments, articular/surgery”, “platelet-rich plasma”, “athletic
injuries/therapy”, “knee injuries/therapy”, “patellar ligament/injuries”,
“tendinopathy/therapy”. Other search terms included medial collateral ligament, grade III
medial collateral ligament, medial collateral ligament repair, patellar tendinopathy,
Achilles tendinitis, lateral epicondylitis, muscle tear, osteoarthritis, and return to play.
The literature review showed support for the potential benefits of PRP therapy for
various orthopaedic injuries but also revealed multiple studies lacking a true control
group. Although a population that would seemingly benefit from PRP therapy, there have
only been three case reports of the use of PRP in patients with MCL injuries and no
published randomized controlled trials. The few case studies indicated a positive benefit,
but in order to evaluate the efficacy of platelet-rich plasma for the treatment of MCL
injuries, a well-designed, randomized, double-blind, placebo-controlled trial is needed.
2.2 REVIEW OF EMPIRICAL STUDIES
2.2.1 Platelet-Rich Plasma Treatment
In orthopaedics and sports medicine, the basic science of PRP has been an
attractive treatment option, with applications in repairing injured tissue, treating
degenerative disorders, and accelerating return to sport1. The applications of PRP range
from chronic conditions to surgical augmentation, tendinopathies, sprains, and tears.

14

Although there have been no published trials on PRP treatment for the MCL, many
studies investigating PRP in similar soft tissue injuries have showed their efficacy in
improving pain and decreasing time lost due to injury. However, many studies lacked
comparison to a true control group and, due to various limitations including lack of
blinding, some studies have found no benefit to the application of PRP.
2.2.1.1 Tendinopathies
Perhaps the most widely studied application of PRP has been to treat
tendinopathies including patellar tendinopathy, Achilles tendinopathy, rotator cuff
tendinopathy, and lateral epicondylitis2. In reviewing the literature, we grouped studies
based on primary outcome, comparison group, and presence or absence of a control
group. We began by examining a recent metanalysis by Fitzpatrick et al. who included
ten randomized controlled trials that found significant results of PRP therapy for Achilles
tendinitis and patellar tendinopathy3.
A closer look at two studies included in this metanalysis, while notable due to the
positive trending of their respective outcome measurement, lacked comparison to a true
control group and instead chose to compare results of PRP treatment to another current
treatment for the particular tendinopathy. Vetrano et al. investigated weekly PRP
injections for two weeks in treatment of patellar tendinopathy. The comparison group
was patients who underwent electric shock wave therapy (ESWT). They found that the
PRP injection group showed significantly better improvement in VAS than patients
randomized to the ESWT group at six months, 2.4 ± 1.9 versus 3.9 ± 2.3 (p = 0.028), and
twelve months, 1.5 ± 1.7 versus 3.2 ± 2.4 (p = 0.009)4. The study also showed decreased
VAS scores in the PRP group from a baseline of 6.6 ± 1.8 to 2.3 ± 1.9 at 6 months and
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1.5 ± 1.7 at 12 months. Another study by Dragoo et al. comparing PRP for patella
tendinopathy with dry needling and found a significant decrease in VAS pain score by
2.4 ± 2.1 points at twelve weeks (p = 0.008) and by 2.6 ± 1.7 (p = 0.003) at twenty-six
weeks5. They did not find a significant difference between the dry needling group and the
PRP group at any time interval, highlighting the need for comparison to a true control
group of standard physical therapy.
A nonrandomized controlled trial by Filardo et al. selected patients for a PRP
group and a control group based on whether the patient had or had not received prior
treatment for patellar tendinopathy6. They found a significant decrease VAS scores in
patients refractory to treatment from baseline of 6.6 ± 1.4 to 4.3 ± 1.7 (p = 0.002) to 3.1 ±
1.2 (p = 0.02) at the six month follow-up for patients in the PRP group6. In comparison,
the control group had a decrease in pain level from 6.7 ± 1.5 to 3.2 ± 2. 4 (p = 0.001)6.
Aside from the VAS scale, pain and disability from patellar tendinopathy is also assessed
by the Victorian Institute of Sports Assessment-Patellar questionnaire7 (VISA-P) (See
Appendix G). A similar unblinded prospective cohort study by Gosens et al. found that a
single PRP injection in patellar tendinopathy resulted in an improvement in VISA-P
scores from 39.1 ± 16.6 to 58.6 ± 25.48. The group was compared to patients who had
either surgery or a prior injection to the injured knee who did not exhibit statistically
significant improvement in VISA-P scores following physical therapy (p = 0.060)8.
Limitations of these studies include nonrandomization and the unblinded protocol
respectively.
Achilles tendinopathy is another application of PRP with a similar population to
the focus of our study as 52% of lifetime prevalence of Achilles tendinopathy is in former
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runners9. In contrast to studies investigating patellar tendinopathy, the literature for
Achilles tendinopathy has more conflicting results. A study by Filardo et al. found that,
after a single PRP injection, Victorian Institute of Sports Assessment - Achilles10 (VISAA) (see Appendix G) scores improved from a baseline of 49.9 ± 18.1 to 62.9 ± 19.8 (p =
0.002) at two months with further improvement to 84.3 ± 17.1 (p = <0.0005) at six
months. Another study by Boesen et al. showed that PRP or high-volume corticosteroid
injections are more beneficial than standard physical therapy exercises in terms of
decreased VAS measures, but the results failed to demonstrate a significant difference
between PRP and corticosteroid injections9. Several other case series have found
improvements on VISA-A scores with the use of PRP for Achilles tendinitis, but they
note that further randomized control trials need to be conducted to explore the promising
results11-16.
In contrast, a few randomized control trials were unable to find a significant effect
of a PRP injection versus a saline injection with the primary outcome of the VISA-A
scores17,18. A study by de Vos et al. that was included in Fitzpatrick et al.’s metanalysis
found that VISA-A scores improved significantly after twenty-four weeks in the PRP
group (by 21.7 points (CI, 13.0-30.5) whereas the placebo saline injection group
decreased by 20.5 points (CI, 11.6-29.4). After regression controlling for predictors of
VISA-A scores, this difference in scores was not significant. Rationales for these
conflicting results again include the lack of comparison to a true control group in the case
of the Boesen et al. study, lack of randomized controlled trials, and randomized study
protocols, and the more chronic nature and duration of symptoms in patients with
Achilles tendonitis.
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PRP therapy has also been investigated for treatment of lateral epicondylitis,
commonly known as “tennis elbow”. Similar to the literature on patellar tendinopathy,
many studies lack comparison to a true control group. A double-blind randomized control
trial by Gosens et al. compared a PRP injection group and a corticosteroid injection
group. The corticosteroid injection group reported lower VAS scores at four and eight
weeks but the PRP group overtook these scores and had a significantly reduced VAS
measure at twenty-six weeks in comparison to the corticosteroid group19. A similar study
by Peerbooms et al. found that the PRP group reported a mean VAS improvement of
44.8% (70.1 to 38.7), whereas the corticosteroid group reported a 32.8% (65.8 to 44.2)20.
Krogh et al. then seemingly addressed this issue of a lack of control group by comparing
three groups: PRP, glucocorticoid, or saline and found no statistical difference between
pain reduction scores at three months21. The mean difference of pain reduction in the PRP
group in comparison to saline group was found to be significant (-2.7 [95% CI, 28.8 to
3.5])21. Importantly, the study experienced significant drop-out and thus the length of the
outcome was dramatically reduced from twelve to three months to conserve the power of
the study. Additionally, 42% of the patients stated that their daily work was the cause of
their lateral epicondylitis, and a rest period after injection was not possible in many cases.
Studies investigating PRP for the treatment of various tendinopathies in both
upper and lower extremities have generally concluded favorable results. Still, some
studies were unable to conclude a significant result. Multiple confounding variables
likely contribute to the inconsistencies in the literature (see section 2.3). Further, a
common theme for the above articles was the presence of a comparison group that was
also a treatment for the particular tendinopathy, or no comparison group at all. Without a
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true control group of a placebo intervention or simply standard physical therapy, it is
difficult to delineate the true effect size of PRP therapy.
2.2.1.2 Acute Muscle Tears and Sprains
Because we will be studying a population with an acute injury, we also reviewed
the literature on the use of PRP in acute muscle strains and ligament sprains. A
randomized controlled trial by Hamid et al. investigated grade IIA acute hamstring tears
in athletes and PRP as an adjuvant therapy to physical therapy22. The mean return to play
for the PRP group was 26.7 ± 7.0 days; the mean return to play for the control group was
42.5 ± 20.6 days22. This is a seemingly large effect, but the control group did not have
their blood drawn meaning patients were likely aware of their group allocation22. Shortly
after this study was published, a double-blind randomized controlled trial by Rossi et al.
examined PRP injection in conjunction with a physical therapy regimen versus a physical
therapy regimen alone on a group of hamstring, quadriceps, and gastrocnemius tears and
found a significant reduction in return to play of 4 days23. The mean time to return to play
was 21.1 ± 3.1 in the PRP group and 25.5 ± 2.8 days for the control group23. In the PRP
group, VAS was measured as a secondary outcome and was found to be significantly
decreased from 5.9 ± 1.1 to 4.7 ± 1.2 (beta regression coefficient = -0.272, p = 0.019)23.
The results meant that an athlete from the treatment group was able to play in one more
game than athletes in the control group23. Additionally, since the VAS pain scores were
lower at all points during the study, patients in the treatment arm could progress faster
through the rehabilitation program23.
The application of PRP is particularly beneficial for elite athletes due to their need
for a rapid return to play. Studies have asserted faster return to play with PRP therapy for
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ulnar collateral ligament (UCL) tears in elite baseball players24 and in athletes with high
ankle sprains25. However, we found that the issue of a lack of control group in the
literature investigating PRP therapy to especially prevalent in studies examining an
athletic population. A rationale for this might be that due to the need for rapid
rehabilitation, athletes might not agree to a randomized control trial in which they might
receive a placebo injection. Podesta et al. examined PRP for partial UCL tears and found
that among baseball, softball, tennis, and volleyball patients who have sustained partial
UCL tears, the average return to play was 12 ± 3 weeks26. Another study by Retting et al.
notes that at 3 months after a UCL tear, only 42 percent of patients are fully recovered
which suggests the potential benefits of PRP for UCL tears even if direct comparison to a
control group has not yet been made27. Another study by Laver et al. examined high
ankle sprains in sixteen elite athletes and found that after a single PRP injection, the mean
return to play was 40.8 ± 8.9 days in the PRP group and 59.6 ± 12.0 in the control group
(p = 0.006)25. Although promising, the study does note that the participants were not
blinded, which could have led to information bias and resulted in a seemingly higher
effect of the PRP injection25.
2.2.1.3 Other Chronic Conditions
Although the acute MCL tear population is generally younger than patients with
primary osteoarthritis of the knee, several high-quality studies have been conducted in
this population. Still, as a common theme to the available literature on PRP therapy,
many studies compared PRP to an injection of hyaluronic acid (HA) which is a common
treatment in osteoarthritis and cartilage degeneration instead of to a placebo injection or
other true control group28. The primary outcomes included the International Knee
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Documentation Committee score (IKDC) and the Western Ontario and McMaster
Universities Osteoarthritis Index29 (WOMAC) (See Appendix G for full forms of both
scales) 28 and found significant improvement at six and twelve months in comparison to
viscosupplementation28,30-34.
In contrast, a recent double-blind randomized control trial by DiMartino et al.
comparing PRP and hyaluronic acid injections for primary osteoarthritis found no
superior improvement in the PRP group over the HA group35. However, the study lacked
a true control group which was addressed by another recent study by Lin et al. comparing
three groups: PRP, HA, and a normal saline injection31. As with the other study, no
significant difference was found between the PRP and HA groups in terms of IKDC
scores at any point during the study31. However, the study found a significant
improvement in the PRP group over the normal saline group throughout the study
duration. The baseline IKDC score for the saline injection group was 33.3 ± 10.52 in
comparison to that of the PRP group, which was 35.71 ± 13.77. At 6 months, the scores
were 34.2 ± 11.11 and 47.33 ± 16.24 respectively31.
2.2.2 Platelet-rich Plasma Improves MCL Healing
Despite the relatively robust literature for platelet-rich plasma in orthopedic
injuries, there have been no prospective randomized control trials testing the efficacy for
recovery from MCL tears. A metanalysis analyzing patellar tendinopathy and medial
collateral ligament trials for PRP found only a case study of a professional soccer player
who was treated with three injections of PRP for an isolated acute grade III MCL tear that
occurred during an in-season match36. The decision was made to inject PRP weekly until
the patient was pain-free. The treatment protocol resulted in an mere 18-day loss of time

21

due to MCL injury and a reported completion of a full soccer match at day 2537. The
authors note the limitations of a single case report but emphasized the benefits of PRP for
this athlete and encourage further prospective trials to understand the true effect size of
PRP for isolated MCL sprains37.
The only other available literature on PRP for MCL sprains is a case report
describing three patients with a history of grade I or II MCL sprains and persistent pain38.
Each patient’s injury mechanism was contact during a recreational football game with a
mean time before starting PRP therapy of ten months38. Each tear was confirmed on MRI
to have residual increased signaling in the superficial or deep MCL. The researchers
prepared a leukocyte-reduced PRP injection for each patient and patients then were
instructed to be non-weight-bearing for a week after the procedure38. A post-treatment
MRI was obtained from each patient which revealed recovery of the MCL. Although the
study mentions that this indicates that PRP seemed to accelerate healing of the MCL in
the study patients, they note that further randomized studies with a larger sample size are
needed to further evaluate this relationship38.
The above case reports all deliver promising results for both chronic and acute
injuries; however, it is difficult to draw conclusions based on any one single case.
Additionally, publication bias might be a factor as it stands to reason that a case where a
patient was treated with PRP but did not return to play is not likely to be published.
Therefore, although there seems to be a potential benefit for treatment of MCL tears with
PRP, a randomized controlled trial powered to detect a difference in effect between an
intervention group and a control group is required to further investigate this relationship.
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2.3 REVIEW OF STUDIES TO IDENTIFY CONFOUNDING VARIABLES
There are multiple potential confounding variables within the procedure for
preparation of PRP. The first example is the various PRP kits that are available. Studies
have used a wide range of these kits, including: Recover System from Biomet8,19,
MyCells Autologous Platelet Preparation System4, GPS III5, Arthrex Double Syringe
System9,39, as well as institution-specific PRP preparation6,11,17,40. A study by Degen et al.
compared commercial separation systems for PRP injections to investigate differences
between different kits as potential confounding variables but found no significant
difference in platelet concentrations between the five kits included in the study. However,
the concentration of white blood cells, neutrophils, red blood cells, and pH were variable
and in some cases statistically significant41. A limitation of this study was the small
sample size and the inclusion of only five preparations when dozens exist.
Multiple studies note that there are several aspects of PRP treatment that have not
been rigorously studied, including the volume of the injection, the inclusion or exclusion
of leukocytes, the most effective preparation, injection technique, depot versus multiple
depots, and single application versus series of injections8,42. A study by Dallaudiere et al.
discusses the potential confounding variable of differing platelet counts that are procured
from the centrifuging process across preparation kits43. The study discusses the
importance of quantifying platelet and leukocyte counts for standardization and notes that
much of the literature does not disclose this information43. Our literature review was
consistent with this assertion; some of the analyzed studies did note the concentration of
platelets in comparison to whole blood and the average number of platelets injected6,26,43,
but the majority did not5,8,9,17,18,21,39. De Vos et al., who examined Achilles tendinopathy,
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noted that their study was unable to quantify the amount of platelets that were injected
after an in-house preparation of the plasma17. Notably, their study did not find PRP to
have a significant effect on VISA-A scores, therefore raising the issue of whether the
platelet concentration was less than the optimal level.
Another study investigating the most effective preparation by Filardo et al. who
examined PRP injections in osteoarthritis, compared the preparation of the injection:
single versus double-spinning44. The study assigned 72 patients to a single spun PRP
injection, and 72 to a double-spun injection and found that there was no significant
difference between the IKDC and VAS scores at two, six, and twelve-month follow-up
appointments44. This addresses a potential confounding variable of differing preparations
of the injections on results, but the results of this study are evidence that the clinical
significance of slightly differing preparations is not enough to skew the study findings.
The authors also note that some studies utilize leukocyte-rich injections, which is defined
as a preparation containing higher white blood cell concentrations than that of whole
blood45, while others opt for leukocyte-poor injections. In general, the study states that
better results are found with leukocyte-poor injections for osteoarthritis with the rationale
that they contain proteases and reactive oxygen species which exacerbate an already
inflammatory pathology44. In contrast, some studies consider the fact that leukocytes are
a source of cytokines and enzymes that might be important in promoting inflammation
and subsequently improved tissue healing as the rationale for a leukocyte rich injection,
particularly in tendinopathies44.
Additionally, several studies use a single injection protocol,5,6,9,23,25,38,46-50 whereas
others use multiple injections37,39,51,52. Two retrospective studies have found that in
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comparison of single versus multiple PRP injections, there was no significant difference
at the respective post-injection intervals33,39. However, a study by Gormeli et al.
compared single versus multiple PRP injection in early versus advanced osteoarthritis
and found that VAS scores for patients with early osteoarthritis improved significantly
more with multiple PRP injections versus a single injection52. The differing protocols for
PRP injection is further outlined in Section 2.4.3 and Table 2.
Aside from confounding variables associated with PRP injection preparation and
administration, multiple confounding variables could affect the healing process of MCL
tears including age, sex, body mass index, days between injury and intervention53,
circumstance of injury, activity level, and post-treatment rehabilitation protocols5,9,23,25,52.
In particular, our literature review revealed the average age of study participants to be
widely variable. Studies investigating PRP for patellar tendinopathy have an average age
range of 27-304-6,8,39 whereas studies for Achilles tendonitis average at 409,11,13,17,18. The
average age of study participant in the lateral epicondylitis patients is 45-5019-21. Studies
have stated that older subjects might be less responsive to the potential benefits of PRP
treatment17. This may be in part to advancing age typically corresponding to more
advanced chronic conditions, and therefore beyond the point where increased
concentration of the body’s natural healing process could significantly recover the
condition. An example of the importance of this confounding variable is the two studies
on Achilles tendonitis by de Vos et al. and de Jonge et al. were unable to conclude that
PRP had a significant improvement on VISA-A scores. Notably, the mean ages of the
study participants were significantly older, 49.718 and 4917 years old respectively.
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Finally, the standard of care for conservative treatment of tendinopathies, sprains,
and tears usually involves a course of physical therapy tailored to the respective injury.
Studies including a rehabilitation protocol often discussed whether there was adherence
to the physical therapy regimen, especially if the program was unsupervised. Fitzpatrick
et al. who studied PRP and gluteal tendinopathy stated that participants were evaluated at
six weeks in order to clear the patient for a progressive walking program with the
previous six weeks acting as the preparation for this advancement54. They concluded that
there was complete adherence to the protocol thus eliminating it as a potential
confounding variable. Further, a study by Hamilton et al. investigating hamstring strains
and PRP treatment was able to use a single-center rehabilitation program and effectively
monitor compliance53. However, Boesen et al. noted that only 70% of participants
performed the recommended exercises that were part of the intervention and control
treatment protocol for Achilles tendonitis9.
2.4 REVIEW OF RELEVANT METHODOLOGY
2.4.1 Study Design and Setting
Multiple randomized controlled trials have been conducted to examine the effects
of PRP in comparison to current therapy in a variety of orthopaedic conditions. Studies
investigating patellar tendinopathy4-6,8,39 are more similar to our proposed study
population, but our literature review revealed more prospective double-blind,
randomized, placebo-controlled trials in the osteoarthritis population31,33-35,52. Further,
trials employing a truly controlled placebo group as the comparison group are limited.
Previous case reports have shown favorable results for PRP treatment in MCL tears37,38
but no prospective studies have been published which indicates the need for a double-
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blind, randomized controlled trial to determine the effect of adjuvant of PRP with
standard physical therapy on the recovery of MCL tears with the use of a placebocontrolled group of a placebo injection and physical therapy for comparison.
Trials generally used a single center design because of sample size and desired
standardization of the injection protocol3-6,8,9,31,33-35,39,44,52,54. We will also be using a
single-center study design. Participants will be recruited using convenience sampling
with computer-generated simple randomization, similar to other studies30,31,33-35,52.
2.4.2 Selection Criteria
2.4.2.1 Inclusion
Available literature on treatment of MCL tears was examined to determine the
inclusion and exclusion criteria for our proposed study. Inclusion criteria in studies
similar in population to our proposed study consistently adhered to the grading system for
MCL tears outlined in Section 1.1.4 (see Table 1)55. Our study will include grade II and
grade III tears. The rationale for the decision to include both grade II and III tears is the
broad description of grade II injuries which can range from minimal signal changes in the
MCL to near complete tears56.
Other important inclusion criteria for our study were developed using exclusion
criteria from studies investigating surgical intervention for grade III MCL tears. Zhang et
al. conducted a study investigating simultaneous reconstruction of the MCL and ACL and
included combined ACL-MCL laxity, subjective medial instability with a grade II or III
MCL injury (medial joint opening > 5 mm based on radiographs compared with the
contralateral knee)57. Therefore, our inclusion criteria will include isolated grade II or III
MCL injuries without medial instability or with medial instability < 5 mm57.
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2.4.2.2 Exclusion
The most important exclusion criterion for our study is candidacy for surgical
intervention. In a review of the literature, this included grade III MCL tears with
associated avulsion at the tibial insertion for which surgical intervention has yielded
positive results58-60. Similarly, combined MCL-ACL injury in active adults is often
surgically managed60. Further, multi-ligament injury is common in higher grade MCL
tears,61 but, for the purposes of our study, it would be difficult to isolate pain specific to
the MCL injury. This exclusion criterion is consistent with Zhang et al. who excluded
posterior cruciate ligament (PCL) injure or posterolateral corner injury57. The study also
excludes active infection, malalignment, or any previous ipsilateral knee surgery as any
of these conditions might delay healing57. Our study will also exclude previous ipsilateral
knee surgery.
Studies on PRP for other orthopaedic injuries, including lateral epicondylitis62 and
high ankle sprains, reported additional exclusion criteria that is applicable to our study.
Mishra et al., who examined lateral epicondylitis and PRP, excluded pregnancy, history
of anemia, history of bleeding disorder, Hemoglobin < 11 g/dL, Hematocrit < 33%,
platelet count outside of the normal range from 150-400 x 100/uL, participation in a
workers’ compensation program, and local steroid injection within 6 weeks to the
ipsilateral elbow62. Rowden et al., who examined PRP and high ankle sprains, excluded
current anticoagulation or antiplatelet therapy, as well as a history of thrombocytopenia49.
A study by Smith et al. examining osteoarthritis and PRP injections excluded patients
with clinically 3+ effusions, previous surgery of the target knee within the past six
months, positive pregnancy test, or intent to become pregnant during treatment period,
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rheumatoid arthritis, history of infection with the target joint, and participation in any
experimental device or drug study within one month before screening visit34. Our study
will similarly exclude previous surgery within the past six months and a history of
infection of the ipsilateral knee.
2.4.3 Intervention
PRP injections have shown promise in orthopaedics and sports medicine in
improving recovery from tendinopathy, acute muscle tears and sprains, ligament sprains,
and osteoarthritis and will be the intervention in the proposed study.
2.4.3.1 Dose
Our review of the literature revealed a widely variable dose and preparation
protocol among preparation kits utilized by individual studies. Currently, there is no
consensus on a superior method of preparation or on optimal amount of infiltration. We
therefore focused on randomized controlled trials to compare the different dosages and
protocols and organized our findings in Table 2 below. One important finding during our
search of the literature revealed that many studies did not report the increase in platelet
concentration from baseline that was being injected5,23,37,49. The optimal increase in
concentration of platelets for effective therapy is unknown, but studies finding significant
benefit with PRP obtained a range of 1.81 ± .34 times baseline to 4.6 ± 1.4 times baseline
concentration31,35.
The literature reflects the heterogeneity of the proposed optimal volume of PRP.
One study noted that there is no consensus on the optimal amount of PRP and injected the
volume equivalent to the volume of the muscle injury23. Other studies used 3 mL5,6,8,11, 4
mL9,17, and 5 mL6,40 injections. Additionally, treatment options varied from a one-time
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injection5,6,9,23,25,38,46-50 to a series of 2-3 treatments4,31,35,37,39,51,52. Notably, ultrasound
guidance was almost universally used4,5,23,25,49.
Table 2: Dosages and Protocols
Study

Injury

Preparation
Kit

Peripheral
Draw

Dragoo
et al. 5

knee

GPS III
(Biomet)

55 mL

Vetrano
et al. 4

knee

MyCells

10 mL

Filardo
et al.6

knee

InstitutionSpecific

150 mL
for three
injections

Gosens
et al.8

knee

Biomet

27 mL

Eirale et
al. 37

MCL

Biomet
Recover

27 mL

Yoshida
et al. 38

MCL

Lin et
al.31

knee

MyCells

RegenKit

AntiClotting/
Additions

Resulting
Injection

Platelet
Conc.

6 mL LRPRP
Acidcitratedextrose

1500g

2 mL LRPRP (22gauge)

1800 rpm
for 15
min

5 mL

Sodium
Citrate

20 mL

7 min at
2000g

3 mL LRPRP

None

1500 rpm
8 min

LP-PRP

10%
Calcium
Chloride

1480 rpm
for 6 min
3400 rpm
for 15
min

4 units of 5
mL LPPRP

knee

InstitutionSpecific

150 mL

Hamid
et al.22

hamstring

GPS III
(Biomet)

60 mL

Rossi et
al. 23

hamstring

Institutionspecific

40 mL

EDTA*

Rowden
et al. 49

ankle

Magellan

50 mL

Citric Acid

20 mL

Trisodium
citrate &
22.8 mM
Calcium
Chloride

Mean
0.89-1.1
x 109
mL
6.5 ± 1.5
million
platelets

3 mL (22gauge)
3 mL (23gauge
needle)

10 mL

Di
Martino
et al.35

Laver et
al. 25

Centrifuge
Speed

Mean
8.2 x
5

10 /mL
1.81 +/0.34 x
baseline
4.6 +/1.4 x
baseline

3 mL

ankle

InstitutionSpecific

Filardo
et al.40

Achilles

InstitutionSpecific

150 mL

10%
Calcium
Chloride

Boesen
et al.9

Achilles

Arthrex

10 mL

No
activator

30

1400g +
3000 rpm
for 3 min

3 mL (20
gauge)
3-4 mL of
LR-PRP

460 g for
8 min
1480 rpm
6 min
3400 rpm
15 min
5 min
1500 rpm

1.5 mL
(21-gauge)

2-3 x
baseline

four 5 mL
PRP

5x
baseline

4 mL

de Vos
et al.17
Gosens
et al.19
Peerbooms et
al.20
Krogh et
al.21
Podesta
et al.

Achilles

Recover
Platelet

Elbow

Biomet

Elbow

Biomet

Elbow
UCL

GPS III
(Biomet)
Arteriocyte

45 mL

Citrate

4 mL

27 mL

8.4% sodium
bicarbonate

3 mL (22gauge)

27 mL

8.4% sodium
bicarbonate

15 min
3200 rpm

3 mL

8x
baseline

5 mL LRPRP

60 mL

*EDTA: Ethylenediaminetetraacetic Acid

2.4.3.2 Duration/Frequency
There is heterogeneity among the reviewed studies regarding the timing,
frequency, and follow-up of PRP treatment. Several studies use one injection at the start
of therapy5,23,49,53,54 and follow patients from four49,53, six23,25,52, eight, twelve weeks5,9,54.
For more chronic conditions, follow-up generally was incremented at 3 and 6 months5,52,
and 1 year8,39,46. Gormeli et al. studied multiple PRP injections for patients with early
knee osteoarthritis in comparison to a single injection and a placebo injection52. A
statistically significant improvement with multiple injections was found. Patients in this
treatment group received 2 mL PRP injections at 7-day intervals for a total of three
injections52. A multiple PRP injection protocol was similarly utilized in other studies for
patellar tendinopathy39, Achilles tendinopathy9, hip osteoarthritis46, and high ankle
sprain25. Because of the acute nature of the MCL injuries we are studying and projected
time to recovery, we will be aligning with a study by Rossi et al. who examined PRP for
muscle tears with the intervention group protocol involving a single injection and
rehabilitation program23.
2.4.3.3 Blinding/Randomization
Different blinding and randomization techniques were reviewed. Rossi et al.
blinded the evaluators, in this case, physical therapists, by providing all participants with
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an envelope containing their allocation to one of the two treatment groups and
subsequently concealing the results from the physical therapist he or she then worked
with23. However, subjective VAS scores were obtained from each patient who was not
blinded to the treatment they received potentially causing information bias in favor of the
PRP injection. In the Dragoo et al. study, participants were assigned to either dry
needling or PRP procedure. Blood was drawn from each patient, patients were
blindfolded, the area of tendinopathy was penetrated ten times, and PRP was injected for
the appropriate patients5. Before the injection, 3 mL of 0.25% bupivacaine with
1:100,000 epinephrine was subcutaneously injected5. However, the study used 6 mL of
PRP, the pressure of which could reasonably have been felt by the patient. Outcomes
could have been subject to information bias if the intervention was detected by the
patient. Although our study will not compare two different treatments for MCL tears, it
will be important to draw blood from all participants to maintain blinding.
Several double blinding protocols were evaluated. The study by Rowden et al.
detailed an effective double blinding protocol. Blood was drawn from all patients by an
Emergency Department Technician and discarded in the placebo group. A research
assistant who was unblinded to the study prepared the injections for the intervention and
placebo groups which included lidocaine and bupivacaine in both groups. The injections
were then blinded to the investigator and the patient with black tape, a technique utilized
by other blinded trials49,62. Importantly, blinding protocols often started with a blood
draw from all participants regardless of treatment allocation5,9,20,21,31,35.
Additionally, the trials investigating PRP for osteoarthritis blinded all patients,
drew blood from all patients, and covered the syringe after the respective injections were

32

prepared. All patients were sent home with instructions to restrict the use of the leg for
the first day and to employ rest, ice, compression, and elevation33,35,52. The study by Lin
et al. spun every participants blood regardless of group allocation so every patient spent
the same amount of time in the office31. Due to the cost of PRP preparation kits, a
reasonable alternative would have been to note the time it takes to prepare a PRP
injection and have the control group stay in the office for the same amount of time
without centrifuging their blood.
2.4.3.4 Control Groups/Standard of Care
Physical therapy regimens are considered the standard of care in the conservative
treatment of MCL injuries. There is no single physical therapy program that has been
shown to be more beneficial, but studies generally emphasize early range of motion
followed by quadriceps and hamstring strengthening63. The study used to calculate our
sample size detailed a rehabilitation program that is commonly used in MCL injury
recovery64. They included quadricep isometric contraction, standing and squat-and-standup movements, and thigh adductor and abductor muscle exercises64. This study was the
only empirical trial found that utilized a control physical therapy group so the
examination of studies that outline the usual practice for MCL physical therapy as
detailed in section 1.1.5 will be used to define our study protocol.
However, the studies investigating PRP use differing comparison groups. Another
one of the studies used in our sample size calculation examined the effect of PRP and
patellar tendinopathy in comparison to focused shock waves4. Although different
populations from our proposed study, some randomized controlled trials used a control
physiotherapy group23,25,53. When blinding was involved, standard therapy and a placebo
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injection was used49. In the setting of PRP for arthritic conditions, PRP injections were
often compared to hyaluronic acid or glucocorticoid injections9,46,52,54. However, some
prospective investigations offering platelet-rich plasma do not include a comparison
group39. The study by Boesen et al. investigating PRP for Achilles tendinopathy used an
isotonic saline injection for the control group9. During the injection, the needle was
inserted slightly away from the tendon just under the skin so as not to affect any tissue
and then held still to resemble the duration of a PRP injection9. Other studies simply
inserted the needle and held it in place for a similar duration to a full PRP injection,
although it was noted in one study that patients might be able to discern whether they
were receiving an injection, which would threaten the patient blinding 17. The doubleblind protocols for osteoarthritis often used a placebo injection as a third comparison
group to PRP versus HA injections30,33,35. After a review of the above studies, we will be
utilizing a placebo injection of isotonic saline in combination with standard physical
therapy for our control group.
2.4.4 Primary and Secondary Outcome Measures
Mean change in Visual Analog Scale (VAS) scores, a subjective measure of pain,
will be the primary outcome for our study. This scale was chosen for the frequency of its
use as a primary or secondary outcome in the reviewed literature and the ability to
calculate a feasible sample size for our study. The scale is a 10 cm line where the left
endpoint is designated “no pain” and the right endpoint is “worst pain imaginable” (see
Figure 1)65. Traditionally, the patient marks the point along the scale that he or she feels
is most reflective of his or her current pain state66. It is designed to gauge the intensity of
pain a patient is feeling at the time of completion. Advantages of the scale include
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feasibility since the time to respond usually takes less than one minute66. The scale also
requires little training to administer. Additionally, a recent study examining orthopaedic
sports medicine patients found no significance difference between VAS scores completed
on paper, on a laptop, or on a mobile device67. Therefore, our study will use Adaptive
Visual Analog Scales software to evaluate pain scores as a continuous variable68. In order
to quantify the effect of PRP intervention, the VAS score will be taken at baseline, at two
weeks, at four weeks, and at six weeks and the net change from baseline will be
calculated, similar to the calculations outlined by Dragoo et al.5.
Return to play was the primary outcome for the case studies on the use of PRP in
MCL tears36-38. Similarly, studies investigating PRP for acute muscle tears23 and
hamstring tendon injuries48,53 use return to play as the primary outcome. As there is no
gold standard criteria for return to play, some studies defined individual criteria53, while
others used full return to practice and games or matches as the definition of return to
play23,53. For the purpose of our study, we were able to make a more robust assessment of
the necessary sample size to detect a significant result using a pain scale as our primary
outcome. Additionally, we chose a pain scale over return to play in order to broaden the
application of PRP for MCL tears beyond athletes. However, enhancement of the healing
process becomes especially important in athletics, with the stakes heightening with each
higher level of play. Therefore, return to activity will be a secondary outcome. Our study
will define return to activity as the ability to participate in the participants baseline
activities before the time of injury with no pain.
Our other secondary outcomes will be the International Knee Documentation
Committee (IKDC) evaluation form and Lysholm scores. In the evaluation of grade III
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MCL tears in the setting of concurrent ACL injury, IKDC and Lysholm were primary
outcomes69. These scales are commonly used patient reported outcome measures in
clinical studies of knee conditions. The IKDC evaluation was created to standardize
various scales that were being used by breaking down knee pain into symptoms, sports
activities, and function70. We will be using the 2000 International Knee Documentation
Committee Subjective Knee Evaluation form71 (see Appendix A). The second scale will
be the Lysholm score which is based on the following symptoms: pain, swelling, limp,
use of cane or crutches, locking sensation in the knee, giving way sensation from the
knee, pain with climbing stairs and with squatting72. The original knee form was
documented by Lysholm et al. (see Appendix B)73.
2.4.5 Sample Size and Statistical Analysis
The literature review did not yield any randomized controlled trials examining the
effect of platelet-rich plasma on recovery from medial collateral ligament tear of any
grade. Therefore, our sample size calculation includes data from three studies. We
calculated relative effect found and extrapolated this information to estimate the effect
size for our intervention and study population. Ding et al. conducted a study evaluating
acupuncture as an augment to physical therapy for MCL tears64. The study measured the
effect of the intervention with the VAS pain scale at baseline and four weeks. At
baseline, the mean VAS score was 5.17 ± 1.5664. At 4 weeks, the mean score was
2.57 ± 1.064. This study was chosen to represent the mean expected improvement in
VAS of our population for the standard of care of MCL tears.
The study populations of the two remaining studies were patients with patellar
tendinopathy. Vetrano et al. measured the effect of PRP on patella tendinopathy in
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comparison to focused shock wave treatment4. At baseline, the mean VAS score for the
PRP group was 6.6 ± 1.84. At 6 months, the mean score was 2.4 ± 1.94. The relative
effect and standard deviation were -4.2 and 1.85 respectively4. The decision was made
not to compare this effect to the study’s comparison group who underwent extracorporeal
shockwave therapy (ESWT) because it did not represent a true control group. Zwerver et
al. examined ESWT therapy for patellar tendinopathy in comparison to a placebo group74.
The majority review of the previous studies that included sample size calculations
utilized an alpha of 0.05 and power of 80%5,8,9,25,46,52,53,74. Therefore, these parameters
were used to calculate our sample size, details of which are located in the Chapter 3 and
in Appendix C.
2.5 CONCLUSION
The literature review supports the use of PRP in a variety of orthopaedic
conditions and highlights the need for a randomized controlled trial investigating the
effect of PRP augmentation for treatment of MCL injury. To date, there is no consensus
on the effect of PRP on MCL tears although case studies have indicated positive results.
A double-blind placebo-controlled randomized trial will most effectively examine the
proposed benefit of PRP on higher grade MCL tears. Recruitment of patients with grade
II and III MCL tears will allow for a clear treatment effect as higher grade tears are more
likely to require more intensive treatment for recovery. Comparison of VAS scores along
with International Knee Documentation Committee (IKDC) forms, Lysholm scores, and
return to activity will effectively quantify the effect of PRP injections in this patient
population.
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CHAPTER 3: STUDY METHODS
3.1 STUDY DESIGN
We propose a randomized, double-blind, placebo-controlled trial investigating the
effect of platelet-rich plasma on recovery from acute isolated grade II and III medial
collateral ligament tears in comparison to the standard of care physical therapy protocol.
Participants will be assigned to either Group 1, the intervention group, or Group 2, the
control group by a computer-generated randomization. Group 1 will receive an injection
of platelet-rich plasma and a physical therapy regimen for MCL tears. Group 2 will
receive a placebo injection of normal saline in addition to the current standard of care
physical therapy for MCL tears.
3.2 STUDY POPULATION AND SAMPLING
The study population will include adults aged 18-45 years old with grade II or III
MCL tears who are evaluated at Yale Orthopaedics and Rehabilitation clinical sites.
MCL tears can be diagnosed clinically or by magnetic resonance imaging (MRI). All
participants will be graded clinically and confirmed with MRI. Eligible patients will be
recruited using convenience sampling from Yale Orthopaedics and Rehabilitation
outpatient clinic for one year and six months. Any patient who meets inclusion and
exclusion criteria will be eligible to participate. During the initial appointment and
clinical confirmation of a grade II or III MCL tear, patients will be introduced to the
study. MRI confirmation of the MCL tear will be conducted after the participants are
committed to the study. If a patient who qualifies for the study has already obtained an
MRI and brings the disc of images and the associated report during the initial consult, this
will satisfy the requirement for MRI confirmation.
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3.2.1 Inclusion Criteria
Inclusion criteria will include acute grade II or III isolated medial collateral
ligament tears. Participants aged 18-45 are eligible to participate. An acute tear will be
defined as injury occurring less than fourteen days prior to treatment. All study
participants will confirm an isolated MCL tear diagnosis with an MRI and baseline
characteristics and baseline Visual Analog Scale (VAS), International Knee
Documentation Committee (IKDC), and Lysholm scores will be collected at the
participant’s MRI follow-up appointment. Before this follow-up appointment, if patients
meet the inclusion criteria, he or she will be contacted and instructed to obtain the
following screening labs: CBC, ESR and CRP. Bloodwork within the previous one month
will also be accepted.
3.2.2 Exclusion Criteria
Exclusion criteria will include grade III MCL tears with associated avulsion at the
tibial insertion, medial instability of > 5 mm, multiligamentous injuries including the
ACL, PCL or posterolateral corner injury, previous ipsilateral knee surgery. Mild MCL
tears (grade I), chronic MCL tears, and tears previously treated with physical therapy will
also be excluded. Further, we will exclude pregnancy, history of bleeding disorder,
Hemoglobin < 11 g/dL, Hematocrit < 33%, platelet count outside of the normal range
from 150-400 x 100/uL, participation in a workers’ compensation program, local
corticosteroid injection within 6 weeks to the ipsilateral knee, current anticoagulation or
antiplatelet therapy, history of thrombocytopenia.
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3.3 SUBJECT PROTECTION AND CONFIDENTIALITY
We will attain Yale Institutional Review Board (IRB) approval for our study prior
to recruitment. We will be adhering to the 100 IRB Protocol for review of human subject
research protocols or FDA-regulated activities involving human participants. The consent
for our study will explain the potential risks of participating in a research protocol and,
more specifically, disclose the potential risks of platelet-rich plasma intra-articular
injection. Clear explanation of measures to maintain confidentiality and privacy practices
will be disclosed. A written, informed consent form will be completed by all study
participants. A sample consent form is can be found in the appendix (Appendix D).
Because of the proposed blinding of our study, study personnel will complete
Health Insurance Portability and Accountability Act (HIPAA) training. Participant data
will be kept confidential within university provided password-protected encrypted
servers.
3.4 RECRUITMENT
Recruitment will primarily take place at Yale Orthopaedics & Rehabilitation
outpatient clinical sites in New Haven, Guilford, Stamford, and Milford, Connecticut.
Patients aged 18-45 who present to Yale Orthopaedics & Rehabilitation will provided
with information about the study if they meet the inclusion criteria. Upon MRI
confirmation of an isolated grade II or III MCL tear, the study team will meet in-person
with the participants who are interested in the study at their follow up visit. In the event
of a patient who has obtained MRI confirmation of an isolated grade II or III MCL tear
prior to the initial appointment at Yale Orthopaedics & Rehabilitation, the patient will be
eligible for participation in the study.
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3.5 STUDY VARIABLES AND MEASURES
3.5.1 Independent Variables
Baseline variables will include age, gender, height, weight, baseline measures
(VAS, IKDC, Lysholm), duration of symptoms, affected knee, level of sports activity
(elite athletes vs recreational athletes) and primary sport played if applicable, and
exercise level/cardiac fitness. Cardiac fitness will be defined as adults who exercise at
medium intensity aerobic activity (biking, walking, jogging/running) 3-5 times a week
for 20-60 minutes. It will be evaluated as a dichotomous variable by meeting this
criterion or not.
The intervention will be a single platelet-rich plasma injection. The PEAK
Platelet-rich Plasma System by DePuy Synthes Mitek Sports Medicine1 will be the
commercially available PRP kit used in this study. For each patient, the first step will be a
30 mL peripheral blood draw with an 18-gauge needle by a nurse. To maintain blinding,
the research assistant will be present at all injection visits in order to complete the
computer-generated randomization for each participant. The injection will be prepared
outside of the patient’s room by a nurse who will be given the patients group allocation.
The preparation of the injectate will begin with the addition of 3 mL of Anticoagulant
Citrate Dextrose A Solution (ACD-A) to the 30 mL syringe. The mixture of blood and
ACD-A will then be placed in the disposable unit provided by Depuy to centrifuge the
blood for one minute. Following the instructions for device use, the nurse will extract the
layer of PRP into a syringe, discarding the layers of red blood cells and platelet poor
plasma, resulting in 3 mL of PRP for injection. The resulting injection will contain 6.8 ±
1.1 times the normal concentration of platelets1. Additionally, white blood cell
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concentration will be 5 times the normal concentration1. No activator (such as calcium
chloride) will be added. The time taken to prepare the injection will be noted. A piece of
black tape will then be placed around the syringe to conceal the contents and ensure
blinding of the primary investigator and patient.
The point of maximal tenderness on the femoral side of the MCL will be marked.
The surrounding skin will be sterilized with 2% chlorhexidine. Using aseptic technique,
the PRP will slowly be injected into the ligament with an ultrasound guidance using a 22gauge 1.5-inch needle. The knee will then be bandaged and the participant will be
instructed to be weight-bearing as tolerated, using crutches as necessary, with progression
to light aerobic activity as tolerated after one week. At one week, participants will also
start physical therapy.
The intervention group will be compared to a placebo injection group as the
control group. To maintain double blinding, a blood sample will be taken from all
patients in the control group by a nurse and removed from the patient’s room. A 3 mL
injection of 0.9% normal saline will be prepared. A piece of black tape will be placed
around the syringe and the nurse will wait to give the primary investigator the injection
until a time comparable to the average time noted to obtain the treatment group injection.
Just as in the intervention group, the point of tenderness on the femoral side of the
MCL will be marked. The surrounding skin will similarly be sterilized with a 2%
chlorhexidine. Using aseptic technique, the injection will occur under ultrasound
guidance using a 22-gauge needle. Patients will be identically bandaged to the PRP group
with the same weight-bearing instructions. The physical therapy program will also begin
one week after the placebo injection.
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All participants, in both study arms, will undergo physical therapy that is the
standard of care for MCL rehabilitation. Standard physical therapy for MCL tears
include quadriceps and leg muscle strengthening and early range of motion protocols
followed by a progressive return to functional and sport-specific movements. The goal of
physical therapy will be full pain-free range of motion and at least 90% strength of the
hamstring and quadriceps as the contralateral knee. The duration of therapy will be 4-6
weeks. See Appendix F for a sample physical therapy program. Patients may also be
given a hinged knee brace on a case by case basis as determined by the treating provider
and use or not of a brace will be included in the data analysis. Adherence to physical
therapy will be monitored through weekly physical therapy progress reports. Patients will
also be asked at their two and six-week follow up about their satisfaction with physical
therapy and whether they have missed any sessions. If non-adherence to the protocol is
found, the participant will be reached out to by phone to encourage full participation.
3.5.2 Dependent Variables
The primary outcome will be Visual Analog Scale scores will be conducted at
baseline, at two weeks, at four weeks, and at six weeks. After the appointment where the
injection was performed, patients will be scheduled for follow-up appointments at two
and six weeks. For patients who prefer electronic surveys, a Qualtrics survey with the
VAS instrument will be sent out at the appropriate intervals by email to each study
participant (see Appendix H for full details). Participants will also have the opportunity to
complete the surveys in the office with the research assistant if preferable, who will then
enter the study participant’s answers to the survey online. If the study participant misses a
follow-up appointment or does not complete an online study, reminder emails will be sent
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to prompt completion of the scales as close to the desired time intervals as possible. If not
completed within three days of the follow-up email, a call will be placed to the study
participant. Importantly, patients will be instructed not to take any non-steroidal antiinflammatory medications on the day of VAS data collection. Mean change in VAS score
from baseline will be calculated at two, four, and six weeks.
The secondary outcomes are return to baseline activity or sport and mean change
in IKDC and Lysholm scores. Scores will be obtained at baseline, at two, at four weeks,
and at six weeks. On the day of completion of the scores, patients will be instructed not to
take any NSAIDs or acetaminophen so as not to minimize pain that the patient would
normally be feeling at the time of completion of the forms. Return to baseline activity or
sport will be discerned with a Qualtrics survey at four and eight weeks asking whether
the patient has returned to baseline activity, and, if so, on what date (see Appendix I).
Return to activity will be assessed as a time to event variable.
3.5.3 Blinding of Intervention
At the time of injection, a computer randomization process will allocate
participants into either the placebo or intervention arm, and the research assistant will
place the assignment into a white envelope without seeing the contents. Injections of PRP
for the intervention group and normal saline for the placebo group will be prepared in the
Yale Orthopaedics & Rehabilitation clinic by an unblinded nurse who will receive the
envelope from the research assistant. The injections will be blinded to the investigator
who will perform the injection by the application of black tape to conceal the syringe
contents. Similarly, the patient will be blinded. Additionally, the radiologist who will be
reading the MRI results at the initial time of injury will be blinded to the study
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intervention and the physical therapist that the participant works with after the procedure
will not be aware of the treatment allocation.
3.5.4 Assignment of Intervention
Computer-generated randomization will assign patients in a 1:1 ratio to either the
PRP or placebo group. The allocation will be concealed in an envelope by the research
assistant until the nurse opens the envelope to prepare the injection. All other study
personnel will be blinded to treatment allocation. Patients will similarly be blinded to
treatment allocation and will have agreed to participate in the study regardless of their
assigned group.
3.5.5 Adherence
Due to the single injection protocol we will be employing, it is critical that
participants attend their clinic appointment where the injection will be performed. For
patients who qualify for the study based on clinical diagnosis and who have expressed
interest in the study, baseline pain scale scores, VAS scores, IKDC form and Lysholm
score will be completed at this appointment, prior to MRI confirmation. After MRI
confirmation of an isolated grade II or III MCL tear, patients will be asked to obtain basic
labs (CBC, ESR, CRP) and to schedule a follow-up appointment to discuss results,
eligibility for our study, and scheduling of the injection. Patients will be reminded of their
appointment one day prior to the scheduled date.
Patients will have the option to undergo the injection the same day as their followup appointment, provided they have completed all the required paperwork ahead of the
appointment. Patients who qualify for the study and are interested in an injection during
their MRI follow-up appointment will be instructed to come to the office early for
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paperwork review with the research assistant. Otherwise, a confirmatory phone call will
also be made to participants the day before the appointment for the injection. After the
injection, patients will be instructed have a two week and six-week follow-up
appointment. To ensure completion of the pain scales as close to the designated time
intervals of two, four, and six weeks, a digital version of the pain scales will be sent out
to participants to obtain the pain scores. Participants will also have the opportunity to fill
out the forms with the research assistant during a follow-up appointment. If a follow-up
appointment is missed, the digital pain scales will be sent out and the appointment be
rescheduled.
Compliance with the physical therapy regimen will be essential to the validity of
our study. To improve generalizability of our study, patients will choose a physical
therapy location that is most convenient for them. We will be requesting physical therapy
progress reports on a weekly basis for study participants. These reports will be signed by
the primary provider overseeing the study. Patients who miss more than one physical
therapy session per week will receive follow-up calls.
3.5.6 Monitoring of Adverse Events
It is estimated that 1 in 70,000 intra-articular injections result in septic arthritis2.
Studies have emphasized the importance of aseptic technique which will be a priority in
our study. After the injection, patients will be called to monitor adverse events. Adverse
events in PRP injections have been shown to be minor, but reports of increased pain and
swelling in the first week have occurred3. Therefore, we will be documenting the number
of participants with increase pain and swelling within the first week and participants with
increased pain lasting longer than a week. Patients will be instructed to call the principal
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investigator with any concerns of prolonged increased pain or other concerns about the
injection. Additionally, a recent metanalysis investigating normal saline as a placebo
intervention for knee osteoarthritis found that adverse events was only reported in one
study with two patients; the remaining thirteen studies reported that the injection was
well-tolerated4.
3.6 DATA COLLECTION
Patients with a clinically diagnosed grade II or III MCL tear who are interested in
participating in the study will complete a demographic and screening survey at baseline
and baseline characteristic data will be compiled (see Appendix E). Baseline
characteristics included in the survey will include age, gender, height, weight, affected
knee, duration of symptoms, sports activity (elite athletes vs recreational athletes) and
sport involved if applicable, and exercise level/cardiac fitness. Patients who meet
inclusion criteria will then complete baseline pain scores including the VAS scale, IKDC
form and Lysholm scores.
Following this data collection, patients will then obtain MRI confirmation of a
grade II or III isolated MCL tear. For those who continue to be eligible for the study after
MRI, baseline CBC, ESR and CRP testing will be obtained. Patients with abnormal labs
will be treated appropriately and can be reconsidered for participation in the study with
findings of normal lab values on recheck of lab work. Patients will be scheduled for twoand six-week follow-up appointments where the three pain scales and forms will be
completed, providers will monitor of adherence to physical therapy regimen, and note
any adverse events.
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The other secondary outcome is return to activity. Participants will complete a
survey at four weeks and eight weeks to assess whether or not they feel they have
returned to baseline activity, or when applicable, returned to sport. This is a time to event
variable.
3.7 SAMPLE SIZE CALCULATIONS
The sample size calculation was calculated from three studies with the primary
outcome of mean change on the VAS scores. VAS is a continuous variable quantified on
a scale from 1-10. The sample size calculation was first calculated using the Power and
Precision software. To ensure the accuracy of the calculator, the G*Power 2 calculator
was used. The calculation was made based on the assumption that a continuous, normally
distributed outcome would be compared between the augmented PRP group and placebo
treatment group using a Student’s t-test.
The mean of the population was extrapolated from the study by Ding et al.5 who
found a mean change in VAS scores after a course of physical therapy, the standard of
treatment for MCL tears, of -2.6 ± 1.31. To relate the relative effects from the Vetrano6
and Zwerver7 studies, the overall mean change and standard deviation were calculated.
The overall relative effect on VAS was calculated to be 3.6; the calculated standard
deviation was 2.296. Finally, the relative effect of PRP on patellar tendinopathy was
compared to the relative effect of physical therapy for MCL tears as an estimation of the
effect that PRP would have on MCL tears. For a two-sided test with α = 0.05 and power
of 80%, 56 patients in each group of the study will need to be recruited. In order to
account for a 15% attrition rate, 8 additional patients in each group will be added. With
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these additional participants, the final sample size needed for our study is 128 patients
with 64 in each group (See Appendix C for the full sample size calculation).
3.8 ANALYSIS
Data will be analyzed by the intention-to-treat principle by including all patients
who will be randomized. Continuous baseline variables will be compared between the
PRP group and the placebo group using a Student’s t-test. This will include age, gender,
height, weight, and duration of symptoms. Dichotomous and categorical baseline
variables will be compared using Chi-Squared test. This will include affected knee, level
of sports activity, cardiac fitness, and primary sport if applicable. A p value of < 0.05 will
indicate a significant result finding in a two-tailed statistical test.
The primary outcome mean change in VAS scores from baseline is a continuous
variable and will be compared between the PRP and placebo groups using a Student’s ttest. To compare within the PRP and placebo groups, a paired t-test will be used. If the
data is not normally distributed a Mann Whitney U test will be used to compare between
the PRP and placebo groups and a Wilcoxon Signed-Rank test will be used to compare
within the PRP and placebo groups. The secondary outcomes are return to activity, the
IKDC questionnaire, and Lysholm scores. Mean change in IKDC and Lysholm scores are
both continuous variables and will be compared between groups using a Student’s t-test
and within groups using an unpaired t-test. Return to activity will be a time to event
variable and will be compared using a Kaplan-Meier analysis. Assessment of the
relationship between change in VAS scores and other potential confounding variables
will be completed using multiple linear regression. These will include age, gender,
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height, weight, sports activity (elite athletes vs nonelite athletes), sport involved if
applicable, and exercise level/cardiac fitness, and use or not of a brace.
3.9 TIMELINE AND RESOURCES
The proposed study period will be two years including recruitment, protocol
completion, and patient follow-up beginning January 1, 2021. The first 16 months of the
study will be utilized for recruitment of the 128 patients with grade II and III MCL tears
aged 18-45. Eligible participants will undergo randomization for PRP therapy and will
receive one injection at the start of treatment on a rolling basis. The course of physical
therapy will last four to six weeks followed by monthly follow-up to assess the status of
full return to activity. See Figure 2 for a diagram of the proposed study timeline. The
personnel requirement for the study will be a principal investigator and co-investigator
for overseeing the study progress, and additional physicians, nurse practitioners, and
physician assistants who will recruit patients seen in his or her clinics. A nurse will be
needed for the preparation of the PRP injection, and a radiologist will be needed to
interpret the MRI images. A research assistant will be needed for data entry and
randomization, and a data analyst will be needed.
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CHAPTER 4: CONCLUSIONS
4.1 ADVANTAGES AND DISADVANTAGES
One of the biggest strengths of our study is the study design of a randomized
controlled trial. Conservative treatment of the MCL is a generally accepted practice under
the correct clinical circumstances, however, recent clinical trials quantifying the effect of
a treatment protocol is lacking. Our study not only will allow us to examine the effect of
PRP on healing of the MCL but will provide a control comparison group using the
current standard of care rehabilitation protocol. Another strength of our study is that both
the intervention group and the control group will be receiving standard of care physical
therapy which will allow us to determine the additional effect that PRP will have on
recovery from MCL injury.
Additional strengths of our study include the MRI confirmation of the grade of
MCL tear, the restriction to acute MCL tears, and the blinding protocol. MRI
confirmation of a grade II or III isolated MCL tear will minimize the risk for residual
laxity and instability after our intervention and treatment protocol by appropriately
excluding patients likely to benefit from definitive surgical treatment. Restriction to acute
MCL tears will allow for the most accurate estimation of the effects of PRP therapy
augmentation. Within the tendinopathy subset of the literature, there were more
consistently significant results in acute injuries like patella tendinopathy naïve to
treatment versus more chronic pathology such as Achilles tendinitis.
Our study protocol is another strength. After reviewing the literature, the extreme
variation in protocol and blinding leads to questions about the generalizability of previous
studies investigating PRP injections. Our study will build on the previous literature by
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effectively blinding all participants and appropriate study personnel in an effort to
eliminate biased data collection. The pain scales should therefore not be influenced by the
anticipated effect that PRP will have on his or her injury, nor will the physical exams
completed by the providers be biased toward a more benign exam in the intervention
group during follow-up. The secondary outcome pain scales, IKDC and Lysholm, are
another strength as it will allow for comparison to previous studies using these scales.
Similarly, our study includes an extensive list of baseline characteristics that will all be
analyzed as potential confounders, thus increasing the likelihood that any positive
findings in our study will be attributable to the effects of PRP therapy.
A study limitation includes the rarity of an isolated grade III MCL tear due to
frequent concomitant injury with the severity of this injury. This led us to the decision to
include grade II MCL tears which encompass the largest range in severity of tear. The
heterogeneity of grade II tears might lead to recruitment of a mild tear that still qualifies
as grade II versus a very nearly complete tear of the MCL. Depending on the relative
severity of grade II tears represented in our study sample, our results could be under or
overestimated. However, grade II and III tears often have similarities that can result in a
longer recovery, which is the target of PRP therapy. Another limitation is the relatively
short follow up period. Although most MCL tears fully resolve by eight weeks,
maintenance of pain free symptoms is not something our study can assess. We are
therefore unable to include information about refractory cases of MCL injury to
treatment, both of our intervention and the standard of care, although this is not the
primary focus of our study. A final limitation includes the cost of PRP as it is generally
not covered by insurance.
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4.2 CLINICAL SIGNIFICANCE
The medial collateral ligament is the most commonly injured knee ligament1-6.
For grade II and III MCL tears, the standard of care involves functional rehabilitation and
physical therapy but results in a loss of injury ranging three to eight weeks7-10. PRP has
the potential to augment recovery of MCL injuries and reduce the burden of injury. By
increasing the concentration of healing components that are naturally found in whole
blood, patients may be able to return to activity sooner and become pain-free faster.
Additionally, lower pain scores might allow patients to proceed more rapidly through a
physical therapy regimen. Successful conservative treatment of MCL injuries would
preclude the need for surgical intervention which is often favored. This study will provide
insight into whether PRP is a viable option for adjunct treatment more severe grades of
MCL tears and open the door for additional investigations.
Future direction for studies to build off of our results include studying the
application of this treatment in the elite athlete population if a significant effect were to
be found. Although our study population is not limited to elite athletes, decreasing the
time lost to injury is highly of particular interest to the athletic community. Effective
conservative treatment of acute injuries in athletes at collegiate and professional level for
example would help to decrease the stress and pressure to recover quickly that may be
felt after injury. If PRP treatment is not found to be significant in our study population,
further investigation into alternative conservative treatment is warranted. However, PRP
therapy is a promising treatment for acute pathologies as an augmentation of the body’s
natural healing response and has the potential to be beneficial in a variety of settings
including injuries to the medial collateral ligament.
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APPENDICES
Figure 2: Study Design
Enrollment: 18 months
Baseline MRI + Pain Scales + Lab work
Allocation
PRP injection + Physical Therapy

Placebo Injection + Physical Therapy

Week 2 Follow-up appointment and completion of VAS, IKDC, Lysholm scores
Week 4 completion of VAS, IKDC, Lysholm, return to activity (and on what date)
Week 6 Follow-up appointment and completion of VAS, IKDC, Lysholm scores
Week 8 Phone call follow-up yes/no return to activity (and on what date)
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Appendix A: International Knee Documentation Committee Evaluation Form

https://www.sportsmed.org/aossmimis/Staging/Research/IKDC_Forms.aspx
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Appendix B: Lysholm Knee Scoring Scale

https://stfsportsmed.com/wp-content/uploads/Lysholm-Knee-Scale.pdf
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Appendix C: Sample Size Calculation
Baseline Follow-up Relative
Measure Effect
6.6 ± 1.8 6
Group 1 (PRP for
6.6 − 2.4
Patellar Tendinopathy)
months:
= 4.2
2.4 ± 1.9
Group 2 (PT control 4.6 ± 2.3 22
4.6 − 4.0
group for EWST
weeks:
= 0.6
intervention)
4.0 ± 3.0
Mean Change
Overall Relative Effect:
Between Group 1
4.2 − .6 = 3.6
and 2
5.17
MCL Treatment
4 weeks:
5.17
± 1.56
Standard of Care
2.57
± 2.57
± 1.0
= 2.6

Standard Deviation
1.82 + 1.92
= 1.85
2

Overal
l
4.2
± 1.85

2.32 + 3.02
= 2.67
2

.6
± 2.67

√

√

√

1.852 + 2.672
= 2.296
2

3.6
± 2.296

1.562 + 1.02
= 1.31
2

2.6
± 1.31

√

𝑆𝑖𝑧𝑒 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 (𝑛): 56
Assuming 15% attrition rate, 8
additional participants will be added to
each arm:
𝐹𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒: 128
𝑆𝑖𝑧𝑒 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 (𝑛): 64

Sample Size Summary:
𝑇𝑎𝑖𝑙𝑠: 𝑇𝑤𝑜
𝑇𝑦𝑝𝑒 𝐼 𝑒𝑟𝑟𝑜𝑟 𝑟𝑎𝑡𝑒, 𝛼 = 0.05
𝑃𝑜𝑤𝑒𝑟, 1 − 𝛽 = 0.80
𝐶𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙: 0.3 − 1.7
𝑇𝑜𝑡𝑎𝑙 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒: 112
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Appendix D: Adult Consent Form for Participation in a Research Project
Adult Consent for Participation in a Research Project
200 FR 9 (2017-2)
Title: Platelet-Rich Plasma for the Treatment of Acute Grade II and III Medial Collateral
Ligament Tears in Patients Aged 18-45
Principal Investigator: Samantha Smith MD
Co-Investigator: Maddie Kratz
Introduction
You are being asked to join a research study. The following information will explain the
purpose of the study, what you will be asked to do, and the potential risks and benefits.
You should ask questions before deciding whether you wish to participate, or at any time
during the course of the study.
Purpose
The purpose of this study is to investigate the potential benefit of Platelet-Rich Plasma
(PRP) in addition to the standard of care physical therapy regimen for Medial Collateral
Ligament (MCL) tears. You are being asked to participate because you have been
identified as someone who meets the inclusion criteria for the study based on the severity
of your MCL tear as diagnosed clinically and/or confirmed with Magnetic Resonance
Imaging (MRI).
Procedures
If you choose to participate in the study, you will be asked to obtain basic blood tests, an
MRI of your knee, and to schedule a follow-up appointment to discuss the results of your
MRI, complete three questionnaires. You will then be randomized to either the treatment
group or the control group. To maintain the integrity of the research protocol, you will
not be told whether you have been assigned to the treatment group or the control group.
The treatment group will receive an injection of platelet-rich plasma into the MCL tear.
This will be prepared by first obtaining some of your blood and spinning it in a machine
(called a centrifugation process) that will separate out the PRP from the whole blood
specimen. Regardless of whether you are randomized to the treatment group or the
control group, you will have your blood drawn. The control group will not receive an
injection of PRP but will instead receive a saline (salt water) injection. You will then
complete a physical therapy course for 4-6 weeks. At 2 weeks, 4 weeks, and 6 weeks, we
will be contacting you to complete the pain scales again. You will also be scheduled for a
follow-up appointment at 4 weeks.
Possible Benefits

This research may or may not benefit you directly. It is possible that receiving PRP may
help improve the healing of your MCL tear. Additionally, knowledge gained from the
results may help us to better understand the potential benefit of platelet-rich plasma
(PRP) in the treatment of Medial Collateral Ligament (MCL) tears.
Possible Risks
Your part in this research study may involve risks associated with intra-articular injection
procedures. Currently, studies have shown a 1 in 70,000 risk of an infection in the knee
joint following an intra-articular injection. However, proper sterile technique has been
shown to decrease incidence of infections caused by knee injections and will be used
during your injection.
There is also slight risk regarding the confidentiality of your participation in this study, if
information about you becomes known to persons outside this study. The researchers are
required to keep your study information confidential, however, so the risk of breach of
confidentiality is very low.
Privacy / Confidentiality
To protect your confidentiality, your name and other identifying information will not be
recorded on any study documents. You will be assigned a study number and the code
linking your number with your name will be stored in secure, encrypted computer
system. We will only collect information that is needed for research. Only the researchers
involved in this study and those responsible for research oversight will have access to the
information you provided.
Except as permitted by law, your health information will not be released in an identifiable
form outside of the Yale University research team and collaborating researchers’
institution. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. Note, however, that your
records may be reviewed by those responsible for the proper conduct of research such as
the Yale University Human Research Protection Program, Yale University Human
Subjects Committee or representatives of the U.S. Department of Health and Human
Services. The information about your health that will be collected in this study includes:
date of birth, age, sex, history of bleeding disorders and anticoagulation status.
Information may be re-disclosed if the recipients are not required by law to protect the
privacy of the information. At the conclusion of this study, any identifying information
related to your research participation will be destroyed, rendering the data anonymous.
By agreeing to participate in this study, you authorize the use and/or disclosure of the
information described above for this research study. The purpose for the uses and
disclosures you are authorizing is to ensure that the information relating to this
research is available to all parties who may need it for research purposes.
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This authorization to use and disclose your health information collected during your
participation in this study will never expire.

Voluntary Participation
Participation in this study is completely voluntary. You are free to decline to participate,
to end participation at any time for any reason, or to refuse to answer any individual
question at any time. Refusing to participate will involve no penalty or loss of benefits
to which you are otherwise entitled (such as your health care outside the study, the
payment for your health care, and your health care benefits). By providing verbal
consent, you have not given up any of your legal rights.
Questions
You have heard the above description of the research study. You have been told of the
risks and benefits involved and, at this point, all of your questions regarding the study
have been answered.
Authorization
I have read (or someone has read to me) this form and have decided to continue to
participate in the project described above. Its general purposes, the particulars of
involvement and possible hazards and inconveniences have been explained to my
satisfaction. My signature also indicates that I have received a copy of this form.
Name of Subject:_____________________________

Signature:___________________________________
Date:______________________________________

___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator Samantha Smith MD or Maddie Kratz PA-SII.
If you would like to talk with someone other than the researchers to discuss problems,
concerns, and questions, offer input, discuss situations in the event that a member of the
research team is not available, or if you have any questions concerning your rights as a
research subject, you may contact the Human Investigation Committee at (203) 7854688.
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Appendix E: Demographic Screening Survey

Demographic/Screening Survey
Today’s date: __________________

Name: ________________________
1. Date of Birth: ___ / ___ / ____
2. Age: _____ years old

Please circle your answer for the following questions:
3. Gender:

Male Female

a. If female, are you or could you be pregnant?
Yes

No

4. Is your injury being followed by a workers’ compensation program?
Yes

No

5. Injured knee:
Left

Right

6. Have you previously injured this knee?
Yes

No

Injury: ________ Date of Injury: ___ / ___ / ____
7. Have you had previous knee surgery on your injured knee?
Yes

No

8. Have you had a corticosteroid injection on this knee in the past?
Yes

No

9. Do you have a history of anemia?
Yes

No

10. Do you have a history of a bleeding disorder?
Yes

No

11. Are you currently prescribed anticoagulation (Warfarin/Coumadin, Xarelto,
etc.) or antiplatelet treatment (Aspirin, Clopidogrel)?
Yes

No

12. Do you have a history of thrombocytopenia (low platelets)?
Yes

No
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Appendix F: Grade II-III MCL Non-Operative Rehabilitation Protocol
Phase timing variable based on severity of injury and patient progression. Must meet
goals to progress to next phase.
Phase 1: ~1-2 weeks
Goals:
1. Control swelling
2. ROM 10-90
3. Good quad control
Ambulation/Brace Use: weight bearing as tolerated with use of crutches, use of hinged
knee brace per treating physician.
Example Exercises:
Frequent icing/cryotherapy
AAROM, AROM 0-90 degrees
Passive extension with heel on bolster or prone hangs
Electrical stimulation in full extension with quad sets and SLR
Quad sets, Co-contractions quads/hams
Straight leg raise (SLR) x 3 on mat in brace
Short arc quads
Side-lying hip abduction exercises
Stationary bike when tolerated
Phase 2: ~3-4 weeks
Goals:
1. ROM 0-120
2. No effusion
3. No extensor lag
4. Normal gait mechanics and full weight bearing by end of phase
5. 60% of quadriceps strength compared with contralateral side
Ambulation/Brace Use: weight bearing as tolerated, discontinue crutches when
ambulating without limp and good quad control, continue use of hinged knee brace as
indicated
Example Exercises:
Straight leg raise (SLR) x 3 on mat in brace
Short arc quads
Stationary bike – progress up to 20 minutes
Leg press (double leg)
Hamstring curls
Standing hip abductor strengthening
Step ups
Phase 3: ~4-6 weeks
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Goals:
1. Normal stair climbing mechanics
2. 80% of quadriceps strength compared with contralateral side
Ambulation/Brace Use: may discontinue use of brace when cleared by physician for
ADLs
Example Exercises:
Continue exercises in phase 2 and add
Stationary bike – continue to add resistance
Elliptical trainer
Jogging (straight ahead only)
Leg press (single leg)
Single leg balance exercises
Hip adductor strengthening
Phase 4: ~6-8 weeks
Goals:
1. Good kinetic control with closed chain exercises and impact drills
Ambulation/Brace Use: use of brace permitted during sports
Example Exercises:
Continue balance and proprioceptive training
Single leg strengthening exercises
Plyometrics
Lateral and sport specific movements
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Appendix G: Primary Outcome Scale Definitions
Victorian Institute of Sports Assessment-Patellar Questionnaire (VISA-P)
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Victorian Institute of Sports Assessment-Achilles (VISA-A)
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Western Ontario and McMaster Universities Osteoarthritis Index
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Appendix H: Qualtrics Visual Analog Scale (VAS) Scores Survey

Appendix I: Qualtrics Return to Activity Survey
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